Alternative Signaling of the Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor

Jan Ehses is conducting research that may contribute to improved treatment of type 2 diabetes, a form of the disease that occurs most frequently in adults and obese individuals. Ehses has a particular focus on glucose-dependent insulinotropic polypeptide (GIP), a potent hormone that accounts for at least 50 per cent of the insulin secreted from the pancreas following a meal. Studies have consistently shown that GIP's ability to cause insulin secretion is compromised in type 2 diabetes. Using state-of-the-art technology, Ehses is investigating the hypothesis that GIP affects tissues through complex intracellular networks, and that the imbalances in metabolism associated with diabetes may affect this transfer of genetic material important for regulation of insulin production. Ultimately, the goal is to provide a map of the numerous ways GIP affects the whole body, leading to information that can be applied to treatment of type 2 diabetes.